fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

Ginkgo Bioworks lays off 158 employees, with more to come

The once-fast-growing life sciences firm is slashing expenses amid financial woes.

RI BUSINESS
R.I. Life Science Hub picks interim president
Patrice Milos, who has 30 years of experience in the life science industry and was a founding member of RI Bio, will make $25,000 a month as the board searches for a permanent CEO.

Moderna’s flu-COVID combo shot hits goal in late-stage trial
The result brings the Cambridge-based company one step closer to a more convenient jab that could help combat vaccine fatigue.

Cow burps are a major source of methane emissions. A Boston startup is working on a vaccine to fix that.
The methane emitted by the world’s billion-plus belching cattle has roughly the same impact on the climate as all the passenger vehicles on the planet, says Colin South, chief executive of ArkeaBio.

Former Takeda Pharmaceutical employee pleads guilty to stealing $2.3 million
Priya Bhambi, 40, of Brookline, pleaded guilty in US District Court in Boston to one count of conspiracy to commit wire fraud and three counts of wire fraud, prosecutors said Thursday.

Moderna’s vaccine for RSV gets FDA approval for people 60 and older
The approval was welcome news for Cambridge-based Moderna, which has desperately needed a money-making follow-up to its COVID vaccine, Spikevax.

Gates Medical Research Institute in Cambridge names new head
Novartis veteran Patrice Matchaba will succeed Emilio Emini, who recently announced that he will retire on June 30.

Tell us: Are you a current or former Takeda employee? We want to hear about it.
Were you surprised by the size of the layoffs? How do you think they will affect what Takeda does in Massachusetts?

More Life Sciences Headlines

Drug giant Takeda plans more than 640 layoffs in Massachusetts

The state's largest drug maker by headcount confirmed Friday that it plans to lay off hundreds of local employees between early July and next March.

RHODE MAP

A sneak peek at the Rhode Island Life Sciences Hub summit

Hundreds of policymakers, thought leaders, and politicians are coming together at the R.I. convention center to discuss where Rhode Island fits in a multibillion-dollar industry.

Moderna wins a battle in vaccine patent dispute with Pfizer-BioNTech

The Cambridge biotech said Friday that the European Patent Office has upheld the validity of one of its key patents, a victory in an ongoing dispute with Pfizer and BioNTech over rival COVID-19 vaccines.

Ginkgo Bioworks stock threatened with delisting

The once-high-flying Boston life sciences firm has had an average closing price of less than $1 per share over 30 consecutive days of trading.

Ginkgo Bioworks to slash labor costs, jobs

After lackluster first-quarter earnings, Ginkgo Bioworks said it will slash labor expenses by at least 25 percent, which will include an unspecified number of job cuts.

Moderna’s mRNA dreams meet reality with first post-COVID shot

The Cambridge biotech's second vaccine, for RSV, is its first chance to show the versatility of mRNA technology to more effectively treat and prevent a range of illnesses from the flu to cancer.

Moderna’s COVID vaccine sales plunge, as analysts debate future of once-hot company

The decline in sales illustrates waning demand for protection from the virus that caused the pandemic.

FDA approves Boston biotech’s drug for ultra-rare disease of immune system

X4 Pharmaceuticals said regulators approved Xolremdi for use in patients 12 years and older with WHIM syndrome, which can make you more vulnerable to infections.